Page 65 - 77_04

G.
LOLLO
ET
AL.

7.
Danhier,
F.,
&
al.
(2010).

To
exploit
the
tumor
microenvironment:
Passive
&
active
tumor

targeting
of
nanocarriers
for
anti-­-cancer
drug
delivery.
Journal
of
Controlled
Release,
148(2),

135-­-146.

8.
Owens
Iii,
D.E.,
&
al.
(2006).

Opsonization,
biodistribution,
&
pharmacokinetics
of
polymeric

nanoparticles.
International
Journal
of
Pharmaceutics,
307(1),

93-­-102.

9.
Gabizon,
A.,

&
al.
(1992).
The
role
of
surface
charge
&
hydrophilic
groups
on
liposome
clearance

in
vivo.
Biochimica
&
Biophysica
Acta
(BBA)
-­-
Biomembranes,
1103(1),

94-­-100.

10.
Howard,
M.D.,
&
al.
(2008).
PEGylation
of
nanocarrier
drug
delivery
systems:
State
of
the
art.

Journal
of
Biomedical
Nanotechnology,
4(2),

133-­-148.

11.
Molineux,
G.
(2002).

Pegylation:
engineering
improved
pharmaceuticals
for
enhanced
therapy.

Cancer
Treatment
Reviews,
28,
Supplement
1,

13-­-16.

12.
Vila-­-Jato,
J.
L.
(2009).
Nanotecnología
Farmacéutica:
Realidades
y
posibilidades

farmacoterapéuticas.
Monografías,
Madrid,
España:
Instituto
de
España,
Real
Academia

Nacional
de
Farmacia.
409.

13.
Byrne,
J.
D.,
&
al.
(2008).
Active
targeting
schemes
for
nanoparticle
systems
in
cancer

therapeutics.
Advanced
Drug
Delivery
Reviews,
60(15),

1615-­-1626.

14.
Wang,
M.

&
al.
(2010).
Targeting
nanoparticles
to
cancer.
Pharmacological
Research,
62(2),

90-­-99.

15.
Kalli,
K.R.,
&
al.
(2008).
Folate
receptor
alpha
as
a
tumor
target
in
epithelial
ovarian
cancer.

Gynecologic
Oncology,
108(3),

619-­-626.

16.
Oyarzun-­-Ampuero,
F.A.,
&
al.
(2011).
A
new
drug
nanocarrier
consisting
of
polyarginine
&

hyaluronic
acid.
European
Journal
of
Pharmaceutics
&
Biopharmaceutics,
79(1),

54-­-57.

17.
Mizrahy,
S.,
&
al.
(2011).
Hyaluronan-­-coated
nanoparticles:
The
influence
of
the
molecular

weight
on
CD44-­-hyaluronan
interactions
&
on
the
immune
response.
J
Control
Release,

156,

231-­-238.

18.
Schliemann,
C.,

&
al.
(2007).
Antibody-­-based
targeting
of
the
tumor
vasculature.
Biochimica
&

Biophysica
Acta
(BBA)
-­-
Reviews
on
Cancer,
1776(2),

175-­-192.

19.
Fay,
F.,

&
al.
(2011).
Antibody-­-targeted
nanoparticles
for
cancer
therapy.
Immunotherapy,

3(3),

381-­-394.

20.
Lian,
T.,

&
al.
(2001).
Trends
&
developments
in
liposome
drug
delivery
systems.
Journal
of

Pharmaceutical
Sciences,
90(6),

667-­-680.

21.
Malam,
Y.,
&
al.
(2009).
Liposomes
&
nanoparticles,
nanosized
vehicles
for
drug
delivery
in

cancer.
Trends
in
Pharmacological
Sciences,
30(11),

592-­-599.

22.
Martin,
F.
(2011).
Comparison
of
Liposomal
Doxorubicin
Products:
Myocet
Vs.
DOXIL.
Apples

to
Apples?
http://www.fda.gov/ohrms/dockets/ac/01/slides/3763s2_08_martin/sld001.htm.

23.
Yang,
F.,
&
al.
(2011).
Liposome
based
delivery
systems
in
pancreatic
cancer
treatment:
From

bench
to
bedside.
Cancer
Treatment
Reviews,
37(8),

633-­-642.

24.
Hervella,
V.,
&
al.
(2008).
Nanomedicine:
New
Challenges
&
Opportunities
in
Cancer
Therapy.

Journal
of
Biomedical
Nanotechnology,
4(3),

276-­-292.

25.
Gelderblom,
H.,
&
al.
(2001).
Cremophor
EL:
the
drawbacks
&
advantages
of
vehicle
selection

for
drug
formulation.
European
Journal
of
Cancer,
37(13),

1590-­-1598.

26.
Alexis,
F.,
&
al.
(2010).
Nanoparticle
Technologies
for
Cancer
Therapy
Drug
Delivery,
M.

Schäfer-­-Korting,
Editor

Springer
Berlin
Heidelberg.

55-­-86.

27.
Desai,
N.,
&
al.
(2009).
SPARC
Expression
Correlates
with
Tumor
Response
to
Albumin-­-Bound

Paclitaxel
in
Head
&
Neck
Cancer
Patients.
Translational
Oncology,

2(2),

59-­-64.

28.
Merle,

(2011).
Presentation
of
Livatag®
(BioAlliance
Pharma)
survival
results.
in

International
liver
cancer
congress.
Hong
Kong.

96